CollPlant Biotechnologies Ltd (CLGN) Expected Move

Tracking the CLGN expected move helps you see how far CollPlant Biotechnologies Ltd's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. CollPlant Biotechnologies Ltd's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the CLGN expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For CLGN, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The CLGN expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks CollPlant Biotechnologies Ltd is unlikely to go.

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds.

It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the CLGN expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The CollPlant Biotechnologies Ltd expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about CLGN.